» Articles » PMID: 33055213

The Eukaryotic Translation Initiation Factor EIF4E Elevates Steady-state MG Capping of Coding and Noncoding Transcripts

Overview
Specialty Science
Date 2020 Oct 15
PMID 33055213
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Methyl-7-guanosine (mG) "capping" of coding and some noncoding RNAs is critical for their maturation and subsequent activity. Here, we discovered that eukaryotic translation initiation factor 4E (eIF4E), itself a cap-binding protein, drives the expression of the capping machinery and increased capping efficiency of ∼100 coding and noncoding RNAs. To quantify this, we developed enzymatic (cap quantification; CapQ) and quantitative cap immunoprecipitation (CapIP) methods. The CapQ method has the further advantage that it captures information about capping status independent of the type of 5' cap, i.e., it is not restricted to informing on mG caps. These methodological advances led to unanticipated revelations: 1) Many RNA populations are inefficiently capped at steady state (∼30 to 50%), and eIF4E overexpression increased this to ∼60 to 100%, depending on the RNA; 2) eIF4E physically associates with noncoding RNAs in the nucleus; and 3) approximately half of eIF4E-capping targets identified are noncoding RNAs. eIF4E's association with noncoding RNAs strongly positions it to act beyond translation. Coding and noncoding capping targets have activities that influence survival, cell morphology, and cell-to-cell interaction. Given that RNA export and translation machineries typically utilize capped RNA substrates, capping regulation provides means to titrate the protein-coding capacity of the transcriptome and, for noncoding RNAs, to regulate their activities. We also discovered a cap sensitivity element (CapSE) which conferred eIF4E-dependent capping sensitivity. Finally, we observed elevated capping for specific RNAs in high-eIF4E leukemia specimens, supporting a role for cap dysregulation in malignancy. In all, levels of capping RNAs can be regulated by eIF4E.

Citing Articles

METTL3 alters capping enzyme expression and its activity on ribosomal proteins.

Del Valle-Morales D, Romano G, Nigita G, Saviana M, La Ferlita A, Le P Sci Rep. 2024; 14(1):27720.

PMID: 39532922 PMC: 11557883. DOI: 10.1038/s41598-024-78152-5.


Nuclear mRNA export.

Chen S, Jiang Q, Fan J, Cheng H Acta Biochim Biophys Sin (Shanghai). 2024; 57(1):84-100.

PMID: 39243141 PMC: 11802349. DOI: 10.3724/abbs.2024145.


Writers, readers, and erasers RNA modifications and drug resistance in cancer.

Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L Mol Cancer. 2024; 23(1):178.

PMID: 39215288 PMC: 11363509. DOI: 10.1186/s12943-024-02089-6.


eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production.

Mars J, Culjkovic-Kraljacic B, Borden K Nucleus. 2024; 15(1):2360196.

PMID: 38880976 PMC: 11185188. DOI: 10.1080/19491034.2024.2360196.


RAM is upregulated during T cell activation and is required for RNA cap formation and gene expression.

Knop K, Gomez-Moreira C, Galloway A, Ditsova D, Cowling V Discov Immunol. 2024; 3(1):kyad021.

PMID: 38572449 PMC: 10989996. DOI: 10.1093/discim/kyad021.


References
1.
Dias A, Dufu K, Lei H, Reed R . A role for TREX components in the release of spliced mRNA from nuclear speckle domains. Nat Commun. 2010; 1:97. PMC: 3793428. DOI: 10.1038/ncomms1103. View

2.
Ulitsky I, Bartel D . lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154(1):26-46. PMC: 3924787. DOI: 10.1016/j.cell.2013.06.020. View

3.
Zahreddine H, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M . The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. Elife. 2017; 6. PMC: 5705209. DOI: 10.7554/eLife.29830. View

4.
Dassi E, Re A, Leo S, Tebaldi T, Pasini L, Peroni D . AURA 2: Empowering discovery of post-transcriptional networks. Translation (Austin). 2016; 2(1):e27738. PMC: 4705823. DOI: 10.4161/trla.27738. View

5.
Carroll M, Borden K . The oncogene eIF4E: using biochemical insights to target cancer. J Interferon Cytokine Res. 2013; 33(5):227-38. PMC: 3653383. DOI: 10.1089/jir.2012.0142. View